| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 0.292 | 0.923 | 1.00 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
catenin beta 1 | 0.303 | 0.885 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 22 | 6 | 1991 | 2017 | ||||||||
|
phosphatase and tensin homolog | 0.305 | 0.923 | 0.26 |
|
phenotype | 0.100 | None | 1.000 | 14 | 3 | 2001 | 2015 | ||||||||
|
B-Raf proto-oncogene, serine/threonine kinase | 0.319 | 0.846 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 8 | 7 | 1968 | 2013 | ||||||||
|
KRAS proto-oncogene, GTPase | 0.320 | 0.923 | 7.9E-04 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
signal transducer and activator of transcription 3 | 0.320 | 0.923 | 1.00 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
actin beta | 0.325 | 0.923 | 0.99 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
mechanistic target of rapamycin kinase | 0.343 | 0.885 | 1.00 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
brain derived neurotrophic factor | 0.345 | 0.923 | 0.66 |
|
phenotype | 0.100 | None | 1.000 | 6 | 1 | 2001 | 2018 | ||||||||
|
androgen receptor | 0.351 | 0.846 | 0.99 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
cytochrome c oxidase subunit II | 0.352 | 0.962 |
|
phenotype | 0.100 | None | 0 | 0 | ||||||||||||
|
vitamin D receptor | 0.352 | 0.885 | 1.7E-05 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
fibroblast growth factor receptor 1 | 0.362 | 0.885 | 1.00 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
KIT proto-oncogene, receptor tyrosine kinase | 0.366 | 0.808 | 0.98 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
notch receptor 1 | 0.369 | 0.885 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 19 | 1 | 1999 | 2019 | ||||||||
|
Fas cell surface death receptor | 0.372 | 0.923 | 0.81 |
|
phenotype | 0.100 | None | 1.000 | 9 | 1 | 1995 | 2016 | ||||||||
|
enhancer of zeste 2 polycomb repressive complex 2 subunit | 0.376 | 0.885 | 1.00 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
HRas proto-oncogene, GTPase | 0.378 | 0.885 | 8.0E-02 |
|
phenotype | 0.100 | None | 1.000 | 5 | 1 | 2006 | 2012 | ||||||||
|
BRCA2 DNA repair associated | 0.379 | 0.846 | 2.4E-25 |
|
phenotype | 0.100 | None | 1.000 | 10 | 2 | 1998 | 2011 | ||||||||
|
lamin A/C | 0.384 | 0.885 | 1.00 |
|
phenotype | 0.100 | None | 0 | 1 | |||||||||||
|
protein tyrosine phosphatase non-receptor type 11 | 0.385 | 0.923 | 1.00 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
solute carrier family 2 member 1 | 0.388 | 0.808 | 0.99 |
|
phenotype | 0.100 | None | 0 | 1 | |||||||||||
|
NRAS proto-oncogene, GTPase | 0.390 | 0.808 | 0.49 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
fibroblast growth factor receptor 3 | 0.391 | 0.846 | 1.6E-05 |
|
phenotype | 0.100 | None | 0 | 0 | |||||||||||
|
ret proto-oncogene | 0.392 | 0.885 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 12 | 1 | 1994 | 2012 |